United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News NKGen Biotech administers first dose of troculeucel for FTD under FDA-cleared compassionate use NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company specializing in natural killer cell therapy, has taken a… byPallavi MadhirajuFebruary 23, 2025